ArticleBMC bioinformatics2026
TP53-META, a meta-analysis tool for comparative transcriptomics of TP53 dependency: examples from target silencing and liver fibrosis.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTP53 is the most frequently mutated transcription factor (TF) in sporadic cancers; and its targets exhibit dysregulation at the level of expression in both cancer and non-cancer pathologies. However, there is not yet a web-based tool that enables meta-analysis and visualization of TP53-related gene expression datasets, although several databases exist to access and annotate TP53 target information. To address this gap, we developed TP53-META, an interactive R Shiny-based web tool that allows users to upload and simultaneously analyze user's or integrated public RNA-seq datasets for effects of TP53 depletion and/or induction on the transcriptome.
resultsTP53-META can be used to visualize significant expression clusters as well as TF-TF, pathway-pathway, disease-gene and treatment-gene networks to determine the extent to which selected treatment contrasts are associated with TP53 regulated transcriptional programs. We demonstrated the utility of TP53-META through two case studies. In the first, using an in-house RNA-seq data from MCF7 cells treated with siRNA against a target gene of interest, i.e., CHRNA5, alone or in combination with an siRNA against TP53, we identified transcriptomic changes induced by CHRNA5 depletion that were either associated with TP53 signaling or maintained independently of TP53 by comparing with selected public datasets in TP53-META. In the second, we demonstrated the user data upload functionality of TP53-META before meta-analysis and extracted commonly modulated TP53-related genes in liver fibrosis using public RNA-seq datasets. TP53-META is available at http://konulabapps.bilkent.edu.tr:3838/TP53-Meta1.5/ and the docker image is downloadable from https://github.com/erenkumak/TP53-Meta .
conclusionsBy facilitating meta-analysis, clustering, and network-based visualizations, TP53-META enables researchers to efficiently integrate and explore TP53-related transcriptomic datasets from diverse sources, and help uncover robust expression patterns, and investigate context-specific TP53 functions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.